These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21698529)

  • 1. [Advanced therapy medicinal products : Scientific, medical, economic, and ethical aspects].
    Seitz R; Schneider CK; Hengel H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):789-90. PubMed ID: 21698529
    [No Abstract]   [Full Text] [Related]  

  • 2. [A comprehensive assessment of ATMP. Difficulties and approaches].
    Thanner M; Nagel E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):843-8. PubMed ID: 21698538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulatory framework of innovative therapies : From bench to bedside].
    Walter C; Rohde B; Wicke DC; Pohler C; Lührmann A; von der Leyen H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):803-10. PubMed ID: 21698532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products].
    Reiss M; Büttel IC; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regulation (EC) No. 1394/2007 on advanced therapy medicinal products : Incorporation into national law].
    Dwenger A; Strassburger J; Schwerdtfeger W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):14-9. PubMed ID: 20033662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
    Buljovčić Z
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reimbursement of new medical therapy].
    Ehlers AP; Wenke A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):849-55. PubMed ID: 21698539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japan responds: stem-cell therapy justified.
    Miyamoto S
    Nature; 2019 May; 569(7754):40. PubMed ID: 31040418
    [No Abstract]   [Full Text] [Related]  

  • 9. [Classification of cell-based medicinal products and legal implications: An overview and an update].
    Scherer J; Flory E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [What is the fair price of innovative therapy?].
    Fischer A; Dewatripont M; Goldman M
    Med Sci (Paris); 2020 Apr; 36(4):389-393. PubMed ID: 32356716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
    Lucas-Samuel S; Ferry N; Trouvin JH
    Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive resource on EU regulatory information for investigators in gene therapy clinical research and advanced therapy medicinal products.
    Cohen-Haguenauer O
    Hum Gene Ther; 2013 Jan; 24(1):12-8. PubMed ID: 23339285
    [No Abstract]   [Full Text] [Related]  

  • 13. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
    Kuhlmann-Gottke J; Duchow K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legal and ethical status of stem cells as medicinal products.
    Tsang L
    Adv Drug Deliv Rev; 2005 Dec; 57(13):1970-80. PubMed ID: 16297498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Texas signals support for unproven stem cell therapies.
    Servick K
    Science; 2017 Jun; 356(6344):1219. PubMed ID: 28642387
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical trials with advanced therapy medicinal products].
    Schüssler-Lenz M; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Important aspects of virus safety of advanced therapy medicinal products].
    Blümel J; Stühler A
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):38-44. PubMed ID: 19937308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
    Renner M; Anliker B; Sanzenbacher R; Schuele S
    Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroregenerative gene therapy: the implications for informed consent laws.
    Sivarajah N
    Health Law Can; 2005 Nov; 26(2):19-28. PubMed ID: 16736945
    [No Abstract]   [Full Text] [Related]  

  • 20. [From basic research to the clinic. Regulations for preclinical and clinical studies with stem cells].
    Steinhoff G; Tiedemann G; Thalheimer M; Ho AD
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Sep; 51(9):973-9. PubMed ID: 18773175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.